Truist Financial Lowers Perspective Therapeutics (NYSE:CATX) Price Target to $10.00

Perspective Therapeutics (NYSE:CATX) had its target price cut by stock analysts at Truist Financial from $21.00 to $10.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 484.80% from the stock’s current price.

Several other equities research analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.22.

Perspective Therapeutics Trading Down 5.0 %

NYSE CATX opened at $1.71 on Monday. The firm’s 50 day moving average is $2.65 and its 200-day moving average is $5.67. Perspective Therapeutics has a 12-month low of $1.62 and a 12-month high of $19.05.

Insider Activity

In other news, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the purchase, the director now directly owns 70,837 shares of the company’s stock, valued at $160,799.99. This trade represents a 45.62 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Johan M. Spoor acquired 22,026 shares of the firm’s stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. This represents a 58.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 115,696 shares of company stock valued at $256,344 over the last ninety days. 3.52% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $34,000. National Bank of Canada FI raised its position in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $51,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.